Related Experiment Video
Updated: May 18, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis
Shuyan Yang1, Changru Jia, Hong Zhu
1Department of Gynecology and Obstetrics, Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, China.
Abstract:
Many publications have evaluated the correlation between Cytochrome P450 1A1 (CYP1A1) Ile462Val polymorphism and cervical cancer risk, but the results remain inconclusive. To provide a more robust estimate of this effect, a meta-analysis was carried out. We systematically searched PubMed, Embase and CBM databases for studies published before May 2012. The association between CYP1A1 Ile462Val polymorphism and cervical cancer risk was assessed by calculating pooled odds ratios (OR) with its 95 % confidence intervals (95 % CI). On the basis of our inclusion criteria, ten studies with a total of 2,423 individuals were included in the meta-analysis. Overall, CYP1A1 Ile462Val polymorphism was associated with increased risk of cervical cancer (Val versus Ile, OR = 1.43; 95 % CI, 1.03-1.97; ValVal versus IleIle, OR = 2.43; 95 % CI, 1.19-4.95; ValVal+ValIle versus IleIle, OR = 1.59; 95 % CI, 1.00-2.53). Ethnic subgroup analyses showed a significant association was found in Caucasians (Val versus Ile, OR = 2.03; 95 % CI, 1.17-3.51; ValVal versus IleIle, OR = 2.74; 95 % CI, 1.30-5.75; ValVal+ValIle versus IleIle, OR = 2.50; 95 % CI, 1.33-4.70), but not in Asians. In conclusion, this meta-analysis suggests that CYP1A1 Ile462Val polymorphism plays an important role in susceptibility to cervical cancer. Further studies with large sample size and careful design need performing to identify this association more comprehensively.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Chi-square Analysis
The chi-square test was developed by Pearson in 1990.
The first step of performing a Chi-square analysis is to establish a null hypothesis, which assumes that there is no real...
